The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...

What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...

In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after ...

Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.

Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...

Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious ...

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning ...

After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI ...

Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock ...

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in ...